Gallen International Expert Consensus recommended that ER expression values between 1% and 9% be considered as equivocal with uncertain benefit of endocrine therapy.13 Moreover, data from MDACC showed that patients with 1–9% ER positivity clinically behaved like those with HR negative breast cancer in terms of pCR and survival outcomes. Here, ESR1 is linked to breast carcinoma.